KALA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KA

Mkt Cap

$3.6M

Volume

280.45K

Next Earnings

November 18th

Loading chart

KA

KALAKALA BIO, Inc. Common Stock

KALA

Pay with—

Available Balance0.00

KA

Mkt Cap

$3.7M

Volume

280.45K

Next Earnings

November 18th

Chart Financials Earnings News About Insider Filings

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesKALA BIO completed a registered direct offering of 10 million shares at $1.00 per share, raising approximately $10 million. The company plans to use the proceeds to repay debt and for general corporate purposes.GlobeNewswire Inc. · Dec 5, 2025

Crude Oil Falls Sharply; Carnival Posts Upbeat EarningsU.S. stocks traded mixed on Monday, with the Dow Jones falling slightly while NASDAQ rose. Carnival reported strong Q3 earnings, while several biotech stocks experienced significant price drops. Oil prices declined, and U.S. pending home sales surged in August.Benzinga · Sep 29, 2025

12 Health Care Stocks Moving In Monday's Intraday SessionMultiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.Benzinga · Sep 29, 2025

Nasdaq Jumps 150 Points; US Pending Home Sales RiseU.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.Benzinga · Sep 29, 2025

Kala Bio (KALA) Q2 Loss Widens 15%Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.The Motley Fool · Aug 8, 2025

KALA BIO Announces Chief Executive Officer TransitionKALA BIO, Inc. announced the resignation of its CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO. Iwicki will continue to serve as Chair of the Board. Bazemore has over 30 years of experience in the pharmaceutical industry and will lead the company as it approaches topline data from the ongoing Phase 2b clinical trial of its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED).GlobeNewswire Inc. · Feb 12, 2025

KALA BIO to Present at Piper Sandler 36th Annual Healthcare ConferenceKALA BIO, a clinical-stage biopharmaceutical company, announced that its Head of R&D and Chief Medical Officer will present at the Piper Sandler 36th Annual Healthcare Conference. The company is focused on developing innovative therapies for rare and severe eye diseases.GlobeNewswire Inc. · Nov 27, 2024

KALA BIO to Present at Jefferies Global Healthcare ConferenceARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024.GlobeNewswire Inc. · May 29, 2024

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.Zacks Investment Research · Apr 4, 2024

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.GlobeNewswire Inc. · Mar 29, 2024

to start trading

KA

KALAKALA BIO, Inc. Common Stock

KALA

Pay with—

Available Balance0.00

Your PositionYou don't own any KALA yet.

Related Tickers

Earnings